Verinata Health, Inc., Redwood City, CA 94063, USA.
Am J Hum Genet. 2013 Feb 7;92(2):167-76. doi: 10.1016/j.ajhg.2012.12.006. Epub 2013 Jan 10.
The purpose of this study was to determine the deep sequencing and analytic conditions needed to detect fetal subchromosome abnormalities across the genome from a maternal blood sample. Cell-free (cf) DNA was isolated from the plasma of 11 pregnant women carrying fetuses with subchromosomal duplications and deletions, translocations, mosaicism, and trisomy 20 diagnosed by metaphase karyotype. Massively parallel sequencing (MPS) was performed with 25-mer tags at approximately 10(9) tags per sample and mapped to reference human genome assembly hg19. Tags were counted and normalized to fixed genome bin sizes of 1 Mb or 100 kb to detect statistically distinct copy-number changes compared to the reference. All seven cases of microdeletions, duplications, translocations, and the trisomy 20 were detected blindly by MPS, including a microdeletion as small as 300 kb. In two of these cases in which the metaphase karyotype showed additional material of unknown origin, MPS identified both the translocation breakpoint and the chromosomal origin of the additional material. In the four mosaic cases, the subchromosomal abnormality was not demonstrated by MPS. This work shows that in nonmosaic cases, it is possible to obtain a fetal molecular karyotype by MPS of maternal plasma cfDNA that is equivalent to a chromosome microarray and in some cases is better than a metaphase karyotype. This approach combines the advantage of enhanced fetal genomic resolution with the improved safety of a noninvasive maternal blood test.
本研究旨在确定从孕妇血浆中检测全基因组胎儿亚染色体异常的深度测序和分析条件。从经中期核型分析诊断为亚染色体重复/缺失、易位、嵌合体和 20 三体的 11 名胎儿的血浆中分离无细胞(cf)DNA。采用 25 个碱基的标签进行大规模平行测序(MPS),每个样本约有 10(9)个标签,然后映射到参考人类基因组 hg19 组装。对标签进行计数,并标准化到固定的基因组 bin 大小为 1 Mb 或 100 kb,以检测与参考基因组相比统计学上明显的拷贝数变化。通过 MPS 盲法检测到所有 7 例微缺失、重复、易位和 20 三体,包括小至 300 kb 的微缺失。在其中 2 例中期核型显示额外未知来源物质的情况下,MPS 确定了易位断点和额外物质的染色体来源。在 4 例嵌合体病例中,MPS 未显示亚染色体异常。这项工作表明,在非嵌合体病例中,通过 MPS 对母体血浆 cfDNA 进行检测可以获得等同于染色体微阵列的胎儿分子核型,在某些情况下优于中期核型。这种方法结合了提高胎儿基因组分辨率的优势和非侵入性母体血液检测的安全性提高的优势。